<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Fang S</submitter><funding>NCI NIH HHS</funding><pagination>1741-7</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4966337</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>34(15)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>To evaluate for an association between 25-hydroxyvitamin D levels (vitamin D) and outcome measures in patients with melanoma after evaluation is controlled for systemic inflammatory response (SIR) on the basis of simultaneous C-reactive protein (CRP) measurement.&lt;h4>Materials and methods&lt;/h4>Plasma samples from 1,042 prospectively observed patients with melanoma were assayed for vitamin D and CRP. The associations of demographics and CRP with vitamin D were determined, followed by a determination of the association between vitamin D and stage and outcome measures from the date of blood draw. The vitamin D level was considered sufficient if it was 30 to 100 ng/mL. Kaplan-Meier and Cox regression analyses were performed.&lt;h4>Results&lt;/h4>The median vitamin D level was 25.0 ng/m</pubmed_abstract><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><pubmed_title>Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.</pubmed_title><pmcid>PMC4966337</pmcid><funding_grant_id>P30 CA023108</funding_grant_id><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>P50 CA093459</funding_grant_id><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Wargo J</pubmed_authors><pubmed_authors>Lee JE</pubmed_authors><pubmed_authors>Sui D</pubmed_authors><pubmed_authors>Lucci A</pubmed_authors><pubmed_authors>Hu MI</pubmed_authors><pubmed_authors>Gershenwald JE</pubmed_authors><pubmed_authors>Reveille JD</pubmed_authors><pubmed_authors>Ross MI</pubmed_authors><pubmed_authors>Chiang YJ</pubmed_authors><pubmed_authors>Gardner JM</pubmed_authors><pubmed_authors>Amos CI</pubmed_authors><pubmed_authors>Wei Q</pubmed_authors><pubmed_authors>Bassett RL</pubmed_authors><pubmed_authors>Cormier JN</pubmed_authors><pubmed_authors>Fang S</pubmed_authors><pubmed_authors>Royal RE</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.</name><description>&lt;h4>Purpose&lt;/h4>To evaluate for an association between 25-hydroxyvitamin D levels (vitamin D) and outcome measures in patients with melanoma after evaluation is controlled for systemic inflammatory response (SIR) on the basis of simultaneous C-reactive protein (CRP) measurement.&lt;h4>Materials and methods&lt;/h4>Plasma samples from 1,042 prospectively observed patients with melanoma were assayed for vitamin D and CRP. The associations of demographics and CRP with vitamin D were determined, followed by a determination of the association between vitamin D and stage and outcome measures from the date of blood draw. The vitamin D level was considered sufficient if it was 30 to 100 ng/mL. Kaplan-Meier and Cox regression analyses were performed.&lt;h4>Results&lt;/h4>The median vitamin D level was 25.0 ng/m</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 May</publication><modification>2026-06-04T15:37:45.133Z</modification><creation>2019-03-27T02:19:28Z</creation></dates><accession>S-EPMC4966337</accession><cross_references><pubmed>27001565</pubmed><doi>10.1200/jco.2015.64.1357</doi><doi>10.1200/JCO.2015.64.1357</doi></cross_references></HashMap>